If big pharma wants something badly enough... the cost and the...

If big pharma wants something badly enough... the cost and the funding are hardly ever an obstacle. Their decisions are based on selecting the right drug, with sufficient patent protection that will serve lucrative, growing markets. ARV's as a group is a technology that doesn't represent an adequate "step-change" in current treatments, such as a vaccine may, and ARV drug treatments are paid for by governments and NGO's, hence unit pricing is under real pressures from day one.

So if your'e wondering why big pharma is not queuing up outside the AVX offices in Richmond, then well done, you're asking exactly the right question. The deal with PGL 'aint goin to fix any of that ...